Current Edition

acute heart failure

Eli Lilly and Boehringer Ingelheim’s Jardiance stays on its heart failure winning streak⁠—this time in acute patients

Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data …

Continue Reading →

J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson’s Invokana is vying for a piece of the lucrative heart failure market. J&J’s Type …

Continue Reading →